Wedbush downgraded Iveric bio to Neutral from Outperform with a price target of $40, up from $35, after the company entered into a definitive agreement under which Astellas Pharma will acquire 100% of its outstanding shares for $40 per share in cash for a total equity value of $5.9B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ISEE: